

# **Moderna COVID-19 Vaccine**

At-A-Glance



Guidance below summarizes basic storage, preparation, scheduling, administration, and dosage for ALL Moderna COVID-19 Vaccine products.





### **Storage and Handling Basics**

Find additional guidance on storing vaccine properly at:

- Vaccine Storage and Handling Toolkit Updated with COVID-19 Vaccine Storage and Handling Information
- Moderna COVID-19 Vaccines | FDA
- Moderna COVID-19 Vaccines | FDA

Vial cap color	B BIVALENT Pink capped vials with yellow-bordered label	BIVALENT Dark blue capped vial with gray-bordered label		
Supplied in multidose vial	2 doses per vial  Do not confuse these with single-dose vials.  Discard vial after 2 doses have been removed.	6 months and older: 5 doses per vial		
Storage Temperature: Before Puncture Do NOT store vaccine in an ultra cold freezer.	Between: -50°C and -15°C (-58°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days 8°C and 25°C (46° and 77°F) for a total of 24 hours. Discard vial and unused vaccine after 24 hours. NOTE: The beyond-use date (30 days) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use date has passed.			
Thawing Frozen Vaccine Do NOT refreeze thawed vaccine.	Between:  2°C and 8°C (36°F and 46°F)  OR  15°C and 25°C (46°F and 77°F)  Amount of time needed to thaw vaccine varies based on temperature and number of vials.			
Storage Temperature: After 1st Puncture Do NOT use after beyond-use date times.	Between: 2°C and 25°C (36°F and 77°F) for up to: ■ 8 hours - bivalent vaccine for ages 6 months through 5 years (pink capped with yellow bordered label) ■ 12 hours - all other Moderna COVID-19 vaccine products Discard vial and any unused vaccine after these time frames.			

**06/13/2023** C\$321571-P



# Moderna COVID-19 Vaccine

At-A-Glance



#### **Preparation and Administration Basics**

Find additional guidance on preparing and administering vaccine properly at:

 Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

- **Preparation**
- If the vaccine is frozen, allow to thaw before preparing the injection. Thaw vaccine in the refrigerator or at room temperature. Unpunctured vials my be stored:
  - o Between 8°C to 25°C (46°F to 77°F) for a total of 24 hours. Track this 24-hour beyond-use time.
  - o Discard unpunctured vials thawed at temperatures above 8°C (46°F) after 24 hours.

- Vaccine Administration Resource Library | CDC
- Moderna COVID-19 Vaccines | FDA
- Moderna (modernacovid19global.com)
- Do NOT refreeze thawed vaccine.
- Check the vial label to ensure the expiration date or beyond-use date/time has not passed.
- Use Moderna expiration date tool at <a href="https://">https://</a> modernacovid19global.com/vial-lookup
- Gently swirl the thawed vaccine vial. Do not shake the vial.

Vial cap color	B Pink capped vials with yellow-bordered label	BIVALENT Dark blue capped vial with gray- bordered label		
Ages	6 months through 5 years	6 months and older		
Beyond-use date/time	After first puncture, use within 8 hours	After first puncture, use within 12 hours		
Do NOT use a punctured vial beyond-use date times.	If using a vial for the 1st time, record the date and time the vial was punctured. <b>NOTE:</b> The beyond-use time replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use time has passed.			

#### Administration

- COVID-19 vaccine may be administered at the clinical visit
   Do NOT "pool" vaccine from more than 1 vial to obtain a as other other routinely recommended vaccines.
  - dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.
  - Gently swirl vaccine to mix. Do NOT shake.

Recipient's Age	Use	Administer	Route	Needle gauge and length	Site
6 months through 5 years of age	Bivalent Pink capped vial with Yellow-bordered label	Previously vaccinated with two doses of Moderna COVID-19 Vaccine 10 µg/0.2 mL NOTE: This vial contains 2 doses.	IM injection	22–25 gauge, 1"	<b>6 months–2 years of age:</b> Vastus lateralis muscle in the anterolateral thigh*
					<b>3–5 years of age:</b> Deltoid muscle in the upper arm <sup>†</sup>
6 months and older	Bivalent Dark blue capped vial with graybordered label	6 months–11 years: 25 μg/0.25 mL	IM injection	22–25 gauge, 1–1½"	6 months-2 years of age: Vastus lateralis muscle in the anterolateral thigh*
		<b>12 years and older:</b> 50 μg/0.5 mL			<b>3 years and older:</b> Deltoid muscle in the upper arm <sup>†</sup>

 $<sup>^{</sup>st}$  The deltoid muscle in the upper arm may be used if the muscle mass is adequate.

 $^{\dagger}$  Vastus lateralis muscle in the anterolateral thigh may be used. **06/13/2023** CS321571-P



# Moderna COVID-19 Vaccine

At-A-Glance



#### **Scheduling Doses**

- The number of bivalent doses varies by age, vaccine, previous COVID-19 vaccines received, and the presence of moderate or severe immune compromise. Review CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States for detailed clinical guidance when scheduling doses, and the Interim COVID-19 Immunization Schedule.
  - Children who turn from 5 to 6 years of age: Use vaccine from the dark blue-capped vial (0.25 mL/25 mcg) for all doses.
- Consider observing persons after vaccination to monitor for allergic reactions and syncope:
  - o 30 minutes for persons with:
    - » An allergy-related contraindication to a different type of COVID-19 vaccine
    - A history of non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine
    - » A history of anaphylaxis after non-COVID-19 vaccines or injectable therapies
  - o 15 minutes: All other persons

#### Document the vaccination

For each vaccine recipient, record

- Both in their medical record and on their vaccination card: vaccination date and vaccine administered (product name, manufacturer, lot number)
- In their medical record: vaccination site and route, vaccinator's name and title.
- On their vaccination card: name/location of clinic or health care professional, note bivalent dose if possible.

Report the vaccination to the appropriate <u>state/local</u> <u>immunization information system (IIS)</u>

#### **Contraindications and precautions**

Screen for contraindications and precautions before administering EACH dose — even if the vaccine was previously administered. Use <a href="CDC's Prevaccination">CDC's Prevaccination</a> Checklist for COVID-19 Vaccination to determine whether the vaccine may be administered.

#### **Contraindications**

History of:

 Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine  Known diagnosed allergy to a component of the COVID-19 vaccine

#### **Precautions**

History of:

- Anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable therapy, including intramuscular, intravenous, or subcutaneous vaccines or therapies, but excluding subcutaneous immunotherapy for allergies (i.e., "allergy shots").
- Non-severe, immediate (onset less than 4 hours) allergic reaction after a dose of one type of COVID-19 vaccine have a precaution to the same type of COVID-19 vaccine
- An allergy-related contraindication to one type of COVID-19 vaccine is a precaution to the other types of COVID-19 vaccines
- Moderate to severe acute illness, with or without fever
- Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
- Myocarditis or pericarditis after a dose of an mRNA or Novavax COVID-19 vaccine

# Report adverse reactions and administration errors

Healthcare professionals are required to report to the <u>Vaccine Adverse Event Reporting System (VAERS)</u> including:

- Vaccine administration errors (whether associated with an adverse event [AE] or not)
- Serious AEs (irrespective of attribution to vaccination)
- Multisystem inflammatory syndrome (MIS) in adults and children
- Cases of myocarditis
- Cases of pericarditis
- Cases of COVID-19 that result in hospitalization or death
- Any additional AEs and revised safety requirements per the <u>Food and Drug Administration's</u> conditions for use of an authorized vaccine throughout the duration of the EUA event.
- Healthcare professionals are encouraged to report to <u>VAERS</u> clinically important adverse events even if unsure whether the vaccine caused the adverse event.

**06/13/2023** CS321571-P